Pliant Therapeutics

Novartis backs away from NASH, furthering its research revamp
Novartis backs away from NASH, furthering its research revamp
BioPharma Dive
Novartis
NASH
Pliant Therapeutics
PLN-1474
Flag link:
Promising IPF treatment results sent Pliant Therapeutics stock soaring
Promising IPF treatment results sent Pliant Therapeutics stock soaring
Investors Business Daily
Pliant Therapeutics
clinical trials
IPF
bexotegrast
Flag link:
Catalysts ahead for the smaller players
Catalysts ahead for the smaller players
EP Vantage
89Bio
Altimmune
AnaptysBio
BioXcel Therapeutics
Calliditas Therapeutics
Eli Lilly
Esperion Therapeutics
Geron
Nektar Therapeutics
Oramed Pharmaceuticals
Pliant Therapeutics
Replimune
Selecta Biosciences
Swedish Orphan Biovitrum
Vera Therapeutics
Viking Therapeutics
Flag link:
Pliant Therapeutics Announces Pricing of Upsized $200.0 Million Public Offering
Pliant Therapeutics Announces Pricing of Upsized $200.0 Million Public Offering
BioSpace
Pliant Therapeutics
IPOs
Flag link:
With new data, Pliant drug shows promise in tough-to-treat lung disease
With new data, Pliant drug shows promise in tough-to-treat lung disease
BioPharma Dive
Pliant Therapeutics
idiopathic pulmonary fibrosis
IPF
PLN-74809
clinical trials
Flag link:
The lung fibrosis pipeline thins
The lung fibrosis pipeline thins
EP Vantage
idiopathic pulmonary fibrosis
IPF
Pliant Therapeutics
PLN-74809
Flag link:
What pandemic? Biotech floats break records
What pandemic? Biotech floats break records
EP Vantage
biotech
IPOs
ADC Therapeutics
Akouos
Applied Molecular Transport
Avidity Biosciences
Ayala Pharmaceuticals
Forma Therapeutics
Fusion Pharmaceuticals
Generation Bio
Hyloris Pharmaceuticals
Lantern Pharma
ORIC Pharmaceuticals
Pliant Therapeutics
PolyPid
Repare Therapeutics
Royalty Pharma
SutroVax
Flag link:
Could This Recent IPO Biotech Become the Next Moderna?
Could This Recent IPO Biotech Become the Next Moderna?
Motley Fool
Pliant Therapeutics
IPOs
Moderna Therapeutics
fibrotic disease
Flag link:
Biotech IPOs near last year's pace, despite COVID-19 pandemic
Biotech IPOs near last year's pace, despite COVID-19 pandemic
BioPharma Dive
IPOs
biotech
Pliant Therapeutics
Legend Biotech
Flag link:
With money flowing, Pliant Therapeutics heads to public well
With money flowing, Pliant Therapeutics heads to public well
Endpoints
IPOs
Pliant Therapeutics
Rare Diseases
oncology
Flag link:
With one rival down, Novartis-partnered biotech scores $100M round to fund mid-stage trials of fibrosis drug
With one rival down, Novartis-partnered biotech scores $100M round to fund mid-stage trials of fibrosis drug
Endpoints
Pliant Therapeutics
IPF
Biogen
Novartis
Flag link:
Novartis bets $80M on Pliant's preclinical NASH prospect
Novartis bets $80M on Pliant's preclinical NASH prospect
Fierce Biotech
Novartis
NASH
Pliant Therapeutics
PLN-1474
Flag link:
Chasing Biogen, the Pliant crew banks a $62M round to fuel their shot at fibrosis targets
Chasing Biogen, the Pliant crew banks a $62M round to fuel their shot at fibrosis targets
Endpoints
Pliant Therapeutics
IPF
idiopathic pulmonary fibrosis
Flag link:
Drugs to Halt, or Reverse, Deadly Lung Scarring? Third Rock Bets $45M it Can Be Done
Drugs to Halt, or Reverse, Deadly Lung Scarring? Third Rock Bets $45M it Can Be Done
Forbes
Third Rock
idiopathic pulmonary fibrosis
Pliant Therapeutics
Flag link: